Literature DB >> 1632835

Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid.

L M Ching1, W R Joseph, B C Baguley.   

Abstract

The new antitumour drug 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA; NSC 640488) was 14-fold more potent than the investigational chemotherapeutic drug flavone-8-acetic acid (NSC 347512) in stimulating tumouricidal activity in cultures of resident murine peritoneal macrophages. The tumouricidal activity of thioglycollate-elicited and Bacillus Calmette-Guérin-primed macrophages was also significantly enhanced by 5,6-MeXAA. Stimulation of macrophage tumouricidal activity by 5,6-MeXAA was not affected by inhibitors of superoxide and nitric oxide production, but was reduced by cyclosporin A, an inhibitor of protein secretion. Inhibitors of neutral proteases had no effect. Cortisone, dexamethasone, indomethacin, dibutyryl cAMP, prostaglandin E2 and prostacyclin, but not prostaglandin F2 alpha, inhibited stimulation, suggesting the involvement of tumour necrosis factor-alpha (TNF). However, antibodies to TNF did not inhibit stimulation. The results suggest that 5,6-MeXAA acts on macrophages in a manner similar to that of endotoxin, utilizing a pathway which includes arachidonic acid metabolism and requiring cell-cell contact with target cells for a tumouricidal effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632835     DOI: 10.1016/0006-2952(92)90058-q

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Immunomodulatory potencies of isolated compounds from Crataegus azarolus through their antioxidant activities.

Authors:  Nadia Mustapha; Imèn Mokdad-Bzéouich; Aicha Sassi; Besma Abed; Kamel Ghedira; Thierry Hennebelle; Leila Chekir-Ghedira
Journal:  Tumour Biol       Date:  2015-12-28

Review 2.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors:  Bruce C Baguley; Dietmar W Siemann
Journal:  Expert Opin Investig Drugs       Date:  2010-11       Impact factor: 6.206

3.  Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.

Authors:  L-C Steve Wang; Lai-Ming Ching; James W Paxton; Philip Kestell; Rachel Sutherland; Li Zhuang; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2008-08-12       Impact factor: 3.850

4.  Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  M Philpott; B C Baguley; L M Ching
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Flavonoids: A versatile source of anticancer drugs.

Authors:  Maheep K Chahar; Neelu Sharma; Mahabeer P Dobhal; Yogesh C Joshi
Journal:  Pharmacogn Rev       Date:  2011-01

7.  Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  E Moilanen; L L Thomsen; D W Miles; D W Happerfield; R G Knowles; S Moncada
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.